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Amandine Bovay,*,† Marco Donia,‡ Per thor Straten,‡ Mark Peakman,x Inge Marie Svane,‡
Sascha Ott,{ Tom Connor,‖,# Barbara Szomolay,* Garry Dolton,*,1 and Andrew K. Sewell*,‖,1
Peptide-MHC (pMHC) multimers, usually used as streptavidin-based tetramers, have transformed the study of Ag-specific T cells
by allowing direct detection, phenotyping, and enumeration within polyclonal T cell populations. These reagents are now a
standard part of the immunology toolkit and have been used in many thousands of published studies. Unfortunately, the TCR-
affinity threshold required for staining with standard pMHC multimer protocols is higher than that required for efficient T cell
activation. This discrepancy makes it possible for pMHC multimer staining to miss fully functional T cells, especially where low-
affinity TCRs predominate, such as in MHC class II–restricted responses or those directed against self-antigens. Several recent,
somewhat alarming, reports indicate that pMHC staining might fail to detect the majority of functional T cells and have prompted
suggestions that T cell immunology has become biased toward the type of cells amenable to detection with multimeric pMHC. We
use several viral- and tumor-specific pMHC reagents to compare populations of human T cells stained by standard pMHC
protocols and optimized protocols that we have developed. Our results confirm that optimized protocols recover greater pop-
ulations of T cells that include fully functional T cell clonotypes that cannot be stained by regular pMHC-staining protocols. These
results highlight the importance of using optimized procedures that include the use of protein kinase inhibitor and Ab cross-
linking during staining to maximize the recovery of Ag-specific T cells and serve to further highlight that many previous
quantifications of T cell responses with pMHC reagents are likely to have considerably underestimated the size of the relevant
populations. The Journal of Immunology, 2018, 200: 2263–2279.
C
lassically restricted T cells are mediators of adaptive
immunity and recognize foreign peptides presented by
MHC class I or II molecules displayed on the surface of
APCs (1, 2). Typically, the foreign peptides that are recognized by
T cells are derived from proteins expressed by pathogens; how-
ever, T cells also play a role in tumor surveillance by recognizing
peptides derived from the dysregulated gene expression that oc-
curs in cancer cells (3). The specificity of peptide–MHC (pMHC)
recognition is conferred by the clonotypic ab TCR, a hetero-
dimeric cell surface receptor that is produced by somatic gene
rearrangement of variable, diversity (of the b-chain), and joining
segments at TCR loci, as well as nucleotide addition and/or de-
letion at recombination junctions (4). V(D)J gene rearrangement
confers high variability to the CDR3 within a TCR, and, in unison
with T cell cross-reactivity, allows TCR repertoires to recognize a
vast number of potential foreign peptides (5). The development of
fluorochrome-conjugated pMHC multimers enabled the visuali-
zation and phenotyping of Ag-specific T cells by flow cytometry
and has transformed the study of T cell responses (6–9). The
original, and still most commonly used, platform for pMHC
multimers consists of four biotinylated pMHC molecules bound to
fluorochrome-conjugated streptavidin (6). The resulting pMHC
“tetramers” have been used in many studies and have become a
standard feature of the T cell immunology toolkit (9). Typical
staining protocols with pMHC tetramers fail to detect cognate
T cells with weak TCR–pMHC affinity, because the affinity
threshold for staining is higher than that required for T cell acti-
vation (10). Thus, regular pMHC tetramer staining fails to detect the
T cells bearing lower-affinity TCRs that often predominate within
antitumor and autoimmune T cell populations (7, 8, 11, 12).
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This problem is further compounded for MHC class II (MHCII)-
restricted T cells, which are known to bear weaker-affinity TCRs
than those raised against MHC class I (MHCI)-restricted peptides
(13). In addition, unlike the MHCI–CD8 interaction (14), the
MHCII–CD4 interaction does not aid binding of pMHC multimers
(15), making staining with pMHCII multimers even more chal-
lenging than for pMHCI.
Much evidence suggests that T cells with low-affinity TCRs
function relatively poorly (10, 16, 17), and the consensus view has
become that T cells with higher-affinity TCRs stain better with
pMHC multimers and exhibit greater sensitivity to cognate Ag.
However, this assumption does not withstand close scrutiny, and
many, more recent, studies demonstrate that pMHC multimers can
fail to detect fully functional T cells (11, 12, 18, 19). Thus, staining
with pMHC multimer is not a definitive surrogate marker of how
sensitive a given T cell will be to cognate Ag or of how effective it
might be in vivo. In accordance with this concept, Ploegh and
colleagues (20) demonstrated that CD8 T cells with high- or low-
affinity TCRs exhibited equivalent antitumor activity. Although the
early results of Yee et al. (21) largely agreed with the view that the
most effective T cells bear high-affinity TCRs and stain well using
standard pMHC tetramer technology, it was noticeable that a mi-
nority of the highly functional cells in this study were poor at
capturing pMHC tetramer from solution. Derby et al. (22) further
showed that, although the functional sensitivity of T cells correlated
with TCR-mediated signaling, it did not necessarily correlate with
TCR affinity or pMHCI tetramer binding. These investigators con-
cluded that caution should be exercised when directly relating TCR
affinity and pMHCI tetramer staining to the functional sensitivity of
T cells (22). Indeed, persistent human viral infections are known to
drive out very large fully functional T cell populations (.5% of
CD8 T cells) that cannot be detected by standard pMHCI tetramer
staining (23). More recent studies by Evavold and colleagues (19,
24, 25) examining CD4 T cell populations in mice have been further
illuminating. Staining with pMHCII tetramers was found to un-
derestimate the H2-IAb–restricted CD4 T cell population specific
for lymphocytic choriomeningitis virus glycoprotein61–80 by 4-fold
and the H2-IAb–restricted population specific for myelin oligoden-
drocyte glycoprotein35–55 by 8-fold (19). Accordingly, these re-
searchers concluded that the use of pMHCmultimers has introduced
a bias that underestimates the lower-affinity, but functional, com-
ponents within diverse Ag-specific TCR repertoires (24). Further
studies demonstrate that low-affinity T cells can represent major
responders in primary CD4 T cell immune responses (25).
The reasons why fully functional T cells might fail to stain with
cognate pMHCmultimer are not completely understood but, in some
cases, could be the result of recent activation in vivo. It is known that
chronic stimulation of T cells during active disease can induce
downregulation of the TCR (26), thereby hindering pMHC multimer
staining of T cells bearing higher-affinity TCRs (12). In addition, the
CD8 coreceptor, which binds to MHCI at a site distinct from the
TCR-docking platform (14, 27), plays a key role in engagement of
pMHCI multimers (28–30). Surface CD8 is also known to down-
regulate upon stimulation, detuning T cells and resulting in a loss of
pMHC multimer binding (31). Consequently, failure to stain with
standard pMHC multimer protocols could be the result of low sur-
face density of a high-affinity TCR/coreceptor or due to expression
of a TCR with lower affinity for the cognate Ag used in staining.
Various improvements to pMHC multimer staining methodologies
aimed at reducing the TCR–pMHC affinity threshold for staining have
been reported. These include the use of beneficial anti-coreceptor Abs
(32–35), inhibiting TCR downregulation with protein kinase inhibitor
(PKI) (36), the use of higher-order multimers with greater numbers of
pMHC per molecule (11, 18), and stabilizing pMHC multimer
binding by Ab cross-linking (12). These approaches can be applied
with pMHCI and pMHCII reagents. Further MHC class–specific
approaches have also been used, including enhancing the MHC in-
teraction with the CD8 coreceptor (29) and use of improved peptide-
flanking regions (37) to enhance staining with pMHCI or pMHCII
multimers, respectively. Various combinations of the above-
mentioned approaches have improved staining by up to 50-fold for
some T cells and can result in considerable savings in terms of the
concentration of pMHC multimer that is required for staining (7, 8).
We recently demonstrated that tumor-specific T cells in tumor-
infiltrating lymphocyte (TIL) populations that failed to stain with
pMHCI tetramers could be fully functional (12). Such T cells could
be stained with pMHC multimers by a combination of applying a
PKI during staining (36) and Ab cross-linking of pMHC reagent
(12). We have also demonstrated that higher-order multimers, in
the form of pMHC dextramers, could detect far more Ag-specific
T cells than parallel staining with pMHC tetramers (11).
Subsequently, Davis and colleagues (18) showed that another
“next-generation” higher-order technology, pMHC dodecamers,
which have 12 pMHC molecules per reagent, were able to detect
2–5-fold more Ag-specific human and murine CD4 and CD8
T cells compared with the equivalent tetramers. These low-
affinity, tetramer-negative but dodecamer-positive, T cells were
observed to exhibit comparable effector cytokine responses to the
high-affinity cells that stained well with pMHC tetramer (18).
Thus, the most recent staining protocols that have been developed
enable detailed study of Ag-specific T cells that fail to stain with
conventional pMHC multimers and confirm that regular staining
with pMHC tetramers, as used in the bulk of studies, might miss
the majority of the relevant T cell responses.
We use pMHC tetramer sorting in conjunction with high-
throughput sequencing to analyze the TCRs used by populations
of CD8 T cells specific for immunodominant epitopes from in-
fluenza, CMV, EBV, and insulin-like growth factor 2 mRNA-
binding protein 2 (IMP2)-specific T cells in the blood of healthy
donors. We additionally examined yellow fever virus–specific
T cells in the blood of a vaccinated donor and melan A–specific
T cells in patient TIL populations. We show that specific TCR
clonotypes can be overlooked by standard pMHC tetramer stain-
ing and formally prove that these clonotypes can be fully func-
tional. These studies further underscore the importance of using
optimized protocols for pMHC multimer staining and suggest that
many previous attempts to enumerate Ag-specific T cell pop-
ulations by pMHC multimer staining will have underestimated the
size of these populations.
Materials and Methods
Patients
Cryopreserved PBMCs from HLA A*0201 (HLA A2)-positive donors with
type 1 diabetes were sourced and handled as previously described (38).
TIL infusion product used to induce a complete lasting remission in stage
IV malignant melanoma Patient MM909.24 and PBMCs taken post-
remission were procured as cryopreserved samples (39).
T cell clones
The HLA A2–restricted EBV-specific CD8 T cell clone GD.GLC17 was
cloned from a T cell line and recognizes the 9-mer BMLF-1–derived
peptide GLCTLVAML (residues 280–288). CR0439.GLC was derived
from the PBMCs of healthy Donor 0439 and also recognizes the
GLCTLVAML peptide. The HLA A2–restricted CD8 T cell clone
CR0439.NLS was derived from the same donor and recognizes a novel 10-mer
peptide derived from IMP2 (residues 367–376; sequence NLSALGIFST).
The HLA A2–restricted melan A–specific CD8 T cell clones
VB6G4.24, CR1, CR7, CR24, CR27, CR29, and CR31 recognize the
wild-type 10-mer peptide EAAGIGILTV (residues 26–35) and its het-
eroclitic variant ELAGIGILTV (heteroclitic residue in bold) (40).
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MEL13 was grown from the PBMCs of a healthy donor and expressed an
identical TCR to sister clone MEL5. The structure and biophysics of
MEL5/MEL13 TCR in complex with HLA A2–EAAGIGILTV and HLA
A2–ELAGIGILTV have been determined previously (40–42). All other
melan A–specific CD8 T cell clones were derived from TILs of a stage
IV malignant melanoma patient (MM909.24) who underwent therapy
with TILs (39) and successfully cleared tumor. Tumor-reactive clone
CR14 from MM909.24 did not stain with HLA A2–ELAGIGILTV tet-
ramer and had unknown specificity. Clones were procured and routinely
expanded as previously described (43).
Lymphoblastoid cell lines and tumor cells
T2 cells and the Donor 0439 lymphoblastoid cell line (LCL) were cultured
as suspension cells at 37˚C and 5% CO2 in RPMI 1640 medium supple-
mented with 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glu-
tamine, and 10% FBS (R10; all from Life Technologies, Paisley, U.K.) and
passaged weekly or as required.
Autologous melanoma cells of HLA A2+ Donor MM909.24 were cul-
tured as an adherent monolayer at 37˚C and 5% CO2 in R10 and detached
from the tissue culture flask by gently washing with calcium and magne-
sium chloride–free Dulbecco’s PBS, followed by incubation with Dul-
becco’s PBS and 2 mM EDTA at 37˚C until cells detached.
PBMCs and T cell lines
PBMCs were obtained from local healthy donors (heparinized) or buffy coats
(EDTA treated) from the Welsh Blood Service, in accordance with appro-
priate ethical approval and informed consent. PBMCs were isolated using
SepMate tubes (STEMCELL Technologies, Vancouver, BC, Canada),
according to the manufacturer’s instructions, and Lymphoprep (Axis
Shield, Oslo, Norway). To create T cell lines, PBMCs were cultured in
priming medium (R10 with 10 mM HEPES buffer, 13 MEM nones-
sential amino acids, 1 mM sodium pyruvate [all from Life Technol-
ogies], and 20 IU/ml IL-2 (Proleukin; Prometheus, San Diego, CA)
with 1025 M LLWNGPMAV peptide from the nonstructural protein 4b of
yellow fever virus (residues 214–222) and anti-human CD28 Ab (10 mg/ml)
for 14 d.
Flow cytometry and cell sorting
Dextramer-PE (Immudex, Copenhagen, Denmark) and premium-grade
streptavidin-PE (catalog number S21388; Life Technologies) were
used with monomeric pMHC as previously described (11). The same
batches of streptavidin-PE and each individual pMHC were used
throughout this study to avoid any possibility of batch-to-batch variation.
Protease inhibitors (Merck, London, U.K.) and PBS (tetramers) or dex-
tramer buffer were added to give a final pMHC multimer concentration
of 0.1 mg/ml (with regard to the pMHC component), were stored in the
dark at 4˚C, and were used within 3 d of assembly. Generally, 0.4 mg of
tetramer or dextramer was used per stain (4 mg/ml with regard to the
pMHC component). Typically, 5 3 104 cells of a T cell clone, 1–2 3 105
TILs, and 2–3 3 106 cells of a T cell line or PBMCs were stained per
tube with dextramer or tetramer first on ice for 30 min. Cells were
washed with PBS and then stained with LIVE/DEAD Fixable Violet
Dead Cell Stain, ViViD (Life Technologies) for 5 min at room temper-
ature, and then a mixture of Abs for 20 min on ice: anti-CD8–allophy-
cocyanin (clone BW135/80; Miltenyi Biotec); anti-CD3–PerCP (clone
BW264/56; Miltenyi Biotec); anti-CD19–Pacific Blue (clone HIB19;
BioLegend), and anti-CD14–Pacific Blue (clone M5E2; BioLegend).
Adapting the above, T cell clones and TILs were stained with ViViD,
anti-CD8 Ab, and anti-CD3 Ab. PBMCs and T cell lines were gated
sequentially: lymphocytes (forward and side scatter), single cells,
viable (ViViDneg)/CD3+/CD14neg/CD19neg cells, and then CD8+/pHLA
multimer+ T cells were sorted for further analyses. TILs were gated
similarly but did not include the dump channel for CD19+ and CD14+
cells. A FACSAria (Central Biotechnology Service, Cardiff University)
was used for cell sorting, with desired cells directed into RNA extraction
buffer (RNeasy Plus Micro Kit; QIAGEN, Heidelberg, Germany) or a
single well of a 96-well U-bottom plate containing T cell media. Data
were analyzed using FlowJo software (TreeStar).
Standard and optimized pHLA multimers staining protocols
The standard protocol is described above (flow cytometry and sorting),
with the optimized protocol featuring two additional steps: cells were
treated with 50 nM dasatinib (PKI) at 37˚C for 30 min and were not
washed prior to staining with tetramer or dextramer (36), and post–
pHLA staining and washing, 0.5 mg (10 mg/ml) of a mouse anti-PE
primary unconjugated mAb (clone PE001; BioLegend) was used. The
complete details have been described previously (12).
TCR sequencing and analysis
RNAwas extracted using an RNeasy PlusMicro Kit (QIAGEN), following
the manufacturer’s instructions. The SMARTer RACE kit (Clontech,
Paris, France) was used to generate full-length cDNA from TCR RNA,
also following the manufacturer’s instructions. Two sets of primers
(external and internal) were designed to perform a nested PCR of the
CDR3 region of the TCR a and b genes. The PCR products were ex-
amined by agarose gel electrophoresis and purified by gel extraction
before sample indexing. All samples were processed further to generate
libraries for high-throughput Illumina sequencing. Libraries were pro-
cessed with the NEBNext Ultra Library preparation kit (New England
Biolabs, Cambridge, U.K.) and run on an Illumina MiSeq instrument
using a MiSeq v2 reagent kit (Illumina, Cambridge, U.K.). TCR gene
usage was determined using reference sequences from the ImMunoGe-
neTics database (http://www.imgt.org), and all TCR gene segments were
designated according to ImMunoGeneTics nomenclature using MiXCR
software (v1.8.1) (44). When cells were sorted from PBMCs for TCR
sequencing, only sequences that were present in at least five reads were
included in the analyses. Unless otherwise stated, we only included
clonotypes present at .1% of the total reads when sequencing tetramer+
cells from cultured cell lines. Functional T cells sorted from the TIL
infusion product and blood of patient MM909.24 were sequenced, and all
TCRs used for analyses. Public TCRs were assigned using a curated
database of TCR sequences with known Ag specificity (45). TCR se-
quences are available at the VDJdb database (45): https://github.com/
antigenomics/vdjdb-db/issues/243.
T cell functional assays
51Cr release cytotoxicity assays were performed as previously described
(12). Briefly, cells were labeled with 51Cr (PerkinElmer, Waltham, MA)
and coincubated with T cells at the desired T cell/target cell ratio.
Supernatants were harvested after 4 h, the amount of chromium released
was assessed by scintillation counting, and percentage lysis was calcu-
lated as previously described (12). Sensitivity to peptide was determined
by activation assay and ELISA, as previously described (40). Briefly,
T cell clones (30,000 cells per well and in duplicate) were incubated
overnight with 60,000 T2 cells, in the presence or absence of the desired
peptide, at different concentrations. Supernatants were harvested, and
MIP-1b was quantified by ELISA, according to the manufacturer’s in-
structions (R&D Systems). PBMCs were prescreened for Ag respon-
siveness by IFN-g ELISPOT, as previously described (46). Briefly,
ELISPOT plates (MSIPS4510; Merck Millipore, Burlington, MA) were
coated with capture Ab [Human IFN-g ELISpotBASIC (ALP); Mabtech,
Nacka Strand, Sweden] for 4 h at 37˚C and blocked with R10 for 1 h at
room temperature, and 0.2 3 106 PBMCs were used per well and in-
cubated overnight (37˚C and 5% CO2) in the presence or absence of
peptide (1025 M). Biotinylated detection Ab and alkaline phosphatase–
conjugated streptavidin were used as per the manufacturer’s instructions
(Mabtech), and plates were developed with an Alkaline Phosphatase
Conjugate Substrate Kit (Bio-Rad, Hercules, CA). Spots were counted
using an AID ELISpot reader (Autoimmun Diagnostika, Strassberg,
Germany). T cells from TILs and PBMCs sorted based on function were
incubated (5 h) with 30 mM of TNF processing inhibitor-0 (TAPI-0) and
anti-TNF (47) and anti-CD107a Abs prior to flow cytometry sorting, as
previously described (48). This allowed viable T cells to be used for TCR
sequencing.
Results
Standard and optimized pMHC multimer staining recover
similar virus-specific T cell populations
Recent studies have suggested that pMHC multimer staining
fails to detect fully functional T cells and, thereby, underesti-
mates the size of Ag-specific T cell populations. It is becoming
widely accepted that this problem is particularly pronounced
when low-affinity TCRs predominate, such as in MHCII-
restricted responses or those directed against self-antigens.
Antiviral TCRs are known to generally bind with relatively
high affinity (13, 49), and it has been assumed that standard
pMHC tetramer–binding protocols are robust in detecting such
cells. We made use of the pMHC tetramer staining strategies
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outlined in Fig. 1 to stain PBMCs from HLA A2+ donors who
were known to make good responses to established immunodo-
minant viral epitopes. Similar-sized populations of CD8 T cells were
observed with standard and optimized staining for HLA A2–
NLVPMVATV (CMV pp65) and HLA A2–CLGGLLTMV (EBV
LMP2A) in Donors 1 and 2 (Supplemental Fig. 1A) and for HLA
A2–GILGFVFTL (influenza matrix) and HLA A2–CLGGLLTMV
in Donors 3 and 4 (Fig. 2A). We next examined the PBMCs of five
donors using HLA A2–GLCTLVAML (EBV BMLF1). Donor 5
showed a similar pattern to that observed with the other viral epi-
topes (Fig. 2B), in that 0.03% of CD3+ cells were CD8+Tet+ with
standard and optimized staining protocols. TCRb sequencing of the
CD8+Tet+ populations stained with each protocol generated just two
sequences. The major sequence, TRBV29-1/TRBJ1-4 with CDR3
sequence CSVGTGGTNEKLFF, accounted for 99.96 and 99.92% of
the reads with standard and optimized staining, respectively. This
TRBV29-1/TRBJ1-4 chain is a well-described “public” TCR that
has been isolated from other individuals (45). The other TCR
b-chain, which made up ,0.1% of total reads in each CD8+Tet+
gate, was TRB27/TRJB2-7 with CDR3 sequence CASTK-
TREKLYF. We conclude that these clonotypes stain well with
standard pMHC tetramer staining protocols and that optimi-
zation using PKI and Ab cross-linking of pMHC tetramer
offers little benefit for recovering these T cells from this do-
nor. Importantly, although the CD8+Tet+ populations were of
similar magnitude, with standard and optimized staining in all
stains shown in Fig. 2 and Supplemental Fig. 1A, it was evi-
dent that the optimized protocol, which prevents “unproduc-
tive” engagement and triggering of TCRs (36) and lowers the
off-rate of bound tetramer (12), stained cells with higher in-
tensity and gave a better separation from the background
CD8+Tetneg population. While undertaking experiments to
prove the usefulness of standard staining technologies for
recovering T cells specific for immunodominant viral epi-
topes, we made the surprising discovery that, in most donors,
the optimized protocol summarized in Fig. 1 detected large
populations of CD8 T cells that bound to HLA A2–
GLCTLVAML tetramer that were not observed when standard
staining protocols were used. This potentially important
finding warranted further investigation.
Standard pMHC tetramer staining sometimes fails to detect
virus-specific T cell populations
Six HLA A2+ donors who produced a good response to HLA
A2–GLCTLVAML were stained with the cognate pMHC
tetramer using the standard and optimized procedures outlined
in Fig. 1. Staining produced similarly sized populations with each
protocol in only one donor (Fig. 2, Donor 5). Surprisingly, this was
not the situation in all of the other donors; the optimized protocol
stained between 4 and 16 times more cells depending on the donor
(Fig. 3, Supplemental Fig. 1B). Donor 0439 was of particular
interest; multiple attempts to stain this donor’s cells with HLA
A2–GLCTLVAML tetramer using regular protocols .15 y
ago, when we were examining CD8 T cell populations specific
for persistent DNA viruses (50), failed. This donor was not
included in these studies, because they were scored as not
responding to this epitope. The ELISPOT with GLCTLVAML
peptide that we undertook to screen potential donors for this
study clearly showed that PBMCs from Donor 0439 responded
to this epitope (Supplemental Fig. 1C). The level of response
observed by ELISPOT in Donor 0439’s PBMCs translated
to ∼0.1% of CD3+ cells and did not equate to the lack of
pMHC tetramer staining with this epitope that was observed
previously in this individual. Subsequent staining with HLA
A2–GLCTLVAML tetramer, using standard and optimized
protocols, detected a substantial CD8+Tet+ population (0.15%
of total CD3+ cells) when the optimized protocol was used.
Staining with standard technology was very poor by com-
parison (Fig. 3B), explaining why we had previously assumed
that this donor did not produce a response to GLCTLVAML
peptide. TCRb sequencing of the CD8+Tet+ populations
showed that there were .100 clonotypes within the sorted
CD8+Tet+ population from this donor. Ten of the eleven clo-
notypes sorted with the standard protocol were not observed in
the population sorted with the optimized protocol. This may
suggest that the GLCTLVAML-specific TCR repertoire is
very large in this donor and, therefore, shows minimal overlap
between replicate samples. However, given the very poor
mean fluorescence intensity of staining of most cells within
the sort gate with standard pMHC tetramer staining, this result
is more likely to reflect capture of background clonotypes that
are not GLCTLVAML-specific. Overall, this result indicates
that standard pMHC tetramer staining with a viral CD8 T cell
epitope can fail to detect functional T cell clonotypes and
further serves to highlight what may have been missed in
studies prior to the introduction of optimized tetramer staining
techniques.
To formally prove that functional T cell clonotypes were being
missed during standard staining with EBV-specific pMHC tet-
ramers, we set out to growmonoclonal populations from the CD8+
FIGURE 1. Study approach. Cell samples were stained in parallel using standard and optimized pMHC multimer staining protocols. The standard
approaches used pMHC tetramer or dextramer, whereas the optimized protocol also included the PKI dasatinib and an anti-fluorochrome Ab. Multimer+
T cells were sorted by flow cytometry for TCR sequencing or cell cloning.
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Tet+ population that was sorted from Donor 0439 following
optimized pMHC tetramer staining. In total, 755 single CD8+
Tet+ cells were sorted into single wells for expansion across two
experiments. Only 4 of 755 clones grew to a sufficient level for
experimentation, but TCR sequencing showed that these had an
identical TCR made from pairing a TRAV5/TRAJ15 chain
(CDR3 CAEKGAGTALIF) and a TRBV29-1/TRBJ1-5 chain
(CDR3 CSVAGTGDLNQPQHF). This clone presumably pos-
sesses a bias toward expansion in culture from the .100 clo-
notypes that were present in the CD8+Tet+ population. We have
FIGURE 2. Ex vivo detection of Ag-specific CD8 T cells using standard pMHC multimer staining technology. (A) PBMCs from HLA A2+ healthy
donors were stained with tetramers bearing the influenza M158–66 peptide (GILGFVFTL; left panel) or the EBV LMP2A426–434 peptide (CLGGLLTMV;
right panel), using tetramer alone (standard) or in combination with PKI and anti-fluorochrome Ab (optimized). Gates were set on single lymphocytes and
live CD3+CD14negCD19neg cells. Irrelevant tetramer made with preproinsulin-derived peptide15–24 (ALWGPDPAAA) (65) or human telomerase reverse
transcriptase (hTERT540–548, ILAKFLHWL) was used to set the gates. The percentage of CD8
+Tet+ T cells is shown for each gate. (B) HLA A2+ PBMCs
were sorted using EBV BMLF1280–288 (GLCTLVAML) standard tetramer staining and optimized staining protocols (left panel). CD8
+Tet+ T cells were
sorted, and TCR b-chain sequencing was performed to compare clonotype capture between protocols. TCR b-chains (right panel) are displayed as sort-
shared (gray) or sort-unique (blue) sections of a pie, with each section for each sort corresponding to a different CDR3b. The number of shared (gray) and
unique (blue) CDR3s for the respective sorts are shown in the center of each pie. TRBV usage is shown in Supplemental Fig. 2. A complete list of sorted b
clonotypes can be found at https://github.com/antigenomics/vdjdb-db/issues/243.
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had similar results with antiviral T cells with other specificities.
We do not know why only some T cell clones are adapted for
in vitro culture, but it is possible that this might reflect a spe-
cific mutation in the clone or some aspect of the phenotype at
the time of culturing. The clone generated was called CR0439.
GLC, and it failed to stain with standard tetramer staining
(Fig. 4A). Clone CR0439.GLC stained well with our optimized
protocol, suggesting that this clone was representative of the
T cell clones stained with the optimized, but not standard, protocol
in Donor 0439 (Fig. 3B). A clone generated previously from
another donor using standard pMHC tetramer staining, GD.GLC17
(expressing public TCR TRAV5/TRAJ31 chain, CDR3 CAEDN-
NARLMF and TRBV20-1/TRBJ1-3 chain, CDR3 CSARVGVGN-
TIYF), stained in parallel with both standard and optimized staining
protocols.
We next set out to prove the CR0439.GLC clone, isolated from
Donor 0439 with our optimized tetramer staining protocol, was
fully functional. Peptide-titration assays showed that clone
CR0439.GLC responded to cognate peptide at respectable exog-
enously applied concentrations , 1 nM (Fig. 4B) and could
recognize the autologous EBV-infected LCL. These results con-
firm that standard pMHC tetramer staining misses fully functional
FIGURE 3. Optimized pMHC multimer staining revealed more EBV-specific clonotypes. PBMCs from HLA A2+ donors were stained ex vivo (A) and
sorted (B) in parallel using HLA A2-GLCTLVAML (EBV, BMLF1280–288) tetramer alone (standard) or in combination with PKI and anti-fluorochrome Ab
(optimized). Gates were set on lymphocytes and live CD3+CD14negCD19neg cells. Staining with irrelevant hTERT540–548 tetramer was used to set the gates.
The percentage of CD8+Tet+ T cells is shown for each gate. b-chain TCRs of Donor 0439’s CD8+Tet+ sorted T cells (B, right panel) are displayed as sort-
shared (gray) or sort-unique (blue) sections of a pie, with each section for each sort corresponding to a different CDR3b. The number of shared (gray) and
unique (blue) CDR3s for the respective sorts are shown in the center of each pie. TRBV usage is shown in Supplemental Fig. 2. A complete list of sorted b
clonotypes can be found at https://github.com/antigenomics/vdjdb-db/issues/243. The gray arrow in the optimized sort indicates the shared clonotype.
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antiviral T cell clonotypes. To emphasize this important point, the
two clones stained in Fig. 4Awere spiked into HLA A2neg PBMCs
at ∼1% total cells prior to tetramer staining with the optimized
and standard protocols outlined in Fig. 1. Clone GD.GLC17 was
recovered by both protocols, although staining was brighter
with the optimized protocol. In contrast, none of the CR0439.
GLC fully functional T cell clones could be recovered with
standard pMHC tetramer staining. Conveniently, the CD8high
nature of cultured T cell clones, as described previously (11),
allowed visualization of the clone within the PBMCs, without
the need for tetramer staining (Fig. 4C). The CR0439.GLC
clone spiked into PBMCs stained well when PKI and cross-
linking Ab were included (Fig. 4C, upper right panel). We
conclude that standard tetramer staining protocols, as have been
used over the last 20 y, fail to detect fully functional antiviral
T cells in some donors. With HLA A2–GLCTLVAML tetramers,
this appeared to be the case in five of six donors tested in this
study. We felt that it was important to extend our findings to
another virus.
Optimized pMHC multimer staining reveals more yellow fever–
specific clonotypes than standard staining protocols
We next stained a panel of T cell lines grown from the PBMCs of a
vaccinated donor (Donor 0345) and nonvaccinated donors (Do-
nors 10 and 11) with tetramers of the immunodominant HLA A2–
restricted yellow fever virus epitope LLWNGPMAV (Fig. 5A).
FIGURE 4. CD8 T cell clones grown from optimally EBV-tetramer stained and sorted PBMCs show effector function. (A) BMLF1-specific CR0439.
GLC CD8+ clone (left panel) grown from the PBMCs of Donor 0439 and GD.GLC17 public CD8+ clone (right panel) staining with standard (tetramer-
alone) and optimized (tetramer + PKI + anti-PE Ab) protocols for HLA A2–GLCTLVAML and irrelevant (ALWGPDPAAA from preproinsulin15–24) (65)
tetramers. Mean fluorescence intensities are shown for each stain. (B) CR0439.GLC CD8+ clone exhibits functional activation when stimulated overnight
with GLCTLVAML peptide (left panel) and robust recognition of EBV-infected cells (right panel), as measured by MIP-1b cytokine release. Uninfected
cells and PHAwere used as negative and positive controls, respectively. (C) Recovery of CR0439.GLC (upper panels) and GD.GLC17 (lower panels) clones
spiked (aiming for 1% of CD3+ cell) into HLA A2neg PBMCs by standard (red boxes, left panels) and optimized (red boxes, right panels) staining protocols
with HLA A2-GLCTLVAML (BMLF1) and irrelevant HLA A2-ALWGPDPAAA.
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Consistent with previous observations with EBV BMLF1–
specific CD8 T cells, more cells were detected with the addition
of PKI and anti-fluorochrome Ab to the protocol. To examine
the TCR clonotypes present in the HLA A2–LLWNGPMAV
pMHC tetramer populations from yellow fever virus 17D–
vaccinated Donor 0345, we made use of pMHC dextramers. We
have previously shown that these higher-order multimers are
better for staining T cells with low-affinity TCRs (11), allowing
maximal recovery of LLWNGPMAV-specific cells for sequence
analyses. We observed that standard staining of Donor 0345
cells with pMHC dextramer more than doubled the population
of CD8 T cells that was stained compared with staining with
tetramer [0.08% (Fig. 5B) compared with 0.03% (Fig. 5A) of
CD3+ cells]. This proportion increased to 0.17% of cells when
the PKI dasatinib was included with the anti-fluorochrome Ab
in an optimized staining protocol (Fig. 5B). TRAV repertoire
analyses of sorted cells by high-throughput sequencing
revealed 9 CDR3s for the standard dextramer-stained cells (750
FIGURE 5. Optimized pMHC multimer staining revealed more yellow fever–specific clonotypes. (A) T cell lines from three HLA A2+ donors were
stained with HLA A2 nonstructural protein 4b of yellow fever virus (residues 214–222) peptide (LLWNGPMAV) or irrelevant HLA A2-ALWGPDPAAA
(preproinsulin15–24) (66) tetramers using standard (tetramer-alone) and optimized (tetramer + PKI + anti-PE Ab) protocols. (B) A T cell line from a yellow
fever–vaccinated HLA A2+ donor (0345) was sorted by flow cytometry in parallel using HLA A2-LLWNGPMAV dextramer with standard or optimized
staining as in (A). The percentage of dextramer+ cells of CD8+ T cells is shown for each gate. Irrelevant dextramer made with HLA A2–ALWGPDPAAA
(65) was used to set the gates for sorting. TCR sequencing and CDR3 analysis of TCR a-chain and TCR b-chain are displayed as sort-shared (gray) or sort-
unique (blue) sections of a pie, with each section for each sort corresponding to a different CDR3. The number of shared (gray) and unique (blue) CDR3s
for the respective sorts are shown in the center of each pie. Public clonotypes are indicated by an asterisk.
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cells sorted) and 27 for the optimized staining (2066 cells
sorted), with eight clonotypes shared between them (Fig. 5B,
right panel). Importantly, the optimized staining protocol
revealed 19 sort-unique CDR3s compared with one from the
standard protocol sort (Fig. 5B). Similar analyses of TRBV use
gave 9 and 18 CDR3s for standard and optimized staining,
respectively, with six shared sequences. Thus, TCR b-chain
sequencing also showed more CDR3s for the optimal protocol
FIGURE 6. Clonotypic analysis of TILs using optimized pMHC staining reveals functional T cells missed by standard approaches. (A) Melan A–specific
T cells were sorted from the TIL infusion product used to induce a complete remission in metastatic melanoma Patient MM909.24 using standard HLA A2–
ELAGIGILTV (heteroclitic residue in bold) tetramer staining (tetramer-alone) and optimized (tetramer + PKI + anti-fluorochrome Ab) protocols. The per-
centage of tetramer+ cells is displayed. Irrelevant HLA A2–ALWGPDPAAA (66) was used to set the gates for sorting. TCR sequencing and CDR3 analysis of
b-chains are displayed as sort-shared (gray) or sort-unique (blue) sections of a pie, with each section for each sort corresponding to a different CDR3. The
number of shared (gray) and unique (blue) CDR3s for the respective sorts are shown in the center of each pie. (B) CDR3s of CD8+ clones grown from Patient
MM909.24 are annotated. CD8+ clones CR24 and VB6G4.24 derived from Patient MM909.24 were stained with standard and optimized protocols using HLA
A2–ELAGIGILTV (ELA) and irrelevant tetramers, with mean fluorescence intensities shown (left panels). Overnight activation against ELA and wild-type
EAAGILGILTV (EAA) peptides (middle panels). Killing of autologous tumor by CR24 and VB6G4.24 at the E:T ratios shown (right panels).
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FIGURE 7. Clones grown from optimally stained and sorted TILs stain true for tetramer. Melan A–specific T cells were sorted from the TILs
of metastatic melanoma Patient MM909.24, who achieved complete remission, using standard (tetramer-alone) (A) and optimized (B) protocols
(tetramer + PKI + anti-fluorochrome Ab). Cells were cloned by limiting dilution and stained with HLA A2–ELAGIGILTV (heteroclitic residue in bold)
and irrelevant HLA A2–ALWGPDPAAA tetramers using standard (A) and optimized (B) protocols. (A and B) Summary of the number of clones that
grew and stained shown within the respective pie (left panel). Representative CD8+ clones encompassing all staining patterns seen (middle and right
panels). (C) Patient MM909.24–derived CD8+ clone CR31, grown from optimally pMHCI–stained and sorted TILs, fails to stain using a standard
protocol with HLA A2–ELAGIGILTV tetramer. HLA A2–ALWGPDPAAA irrelevant tetramer was used as control. Mean fluorescence intensities are
displayed. CR31 responds well to ELA and wild-type EAAGIGILTV (EAA) peptides. CR31 exhibits robust recognition of autologous tumor cells. T
cell alone and PHA as positive control are shown.
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(n = 12) compared with the standard stained and sorted cells
(n = 3) (Fig. 5). TRBV dominance was shared between
TRBV20-1 and TRBV15 (Supplemental Fig. 2) and between
TRBJ2-7 and TRBJ2-1, with a similar distribution seen for the
standard and optimally sorted dextramer+ populations. Optimized HLA
A2–LLWNGPMAV dextramer staining revealed public clono-
types (45, 51) that were not detected by standard dextramer
staining (Fig. 5B, right panels, asterisks), further underscoring
the importance of implementation of this methodology.
Standard pMHC tetramer staining fails to detect tumor-specific
T cell clones in TILs
We extended the study to a clinical sample by staining melanoma-
derived TILs from patient MM909.24, who achieved complete
lasting remission following adoptive transfer of “young TILs” at
Herlev University Hospital (39). As previously described, stan-
dard and optimized pMHC tetramer staining approaches were
used; consistent with our previous studies of this patient (12),
more HLA A2–ELAGIGILTV tetramer+ T cells were detected
with the optimized protocol that contained PKI and Ab cross-
linking than without these additions (Fig. 6A). Again, this
translated to a greater proportion of TRBV clonotypes being
revealed, with 19 unique clones for the optimized protocol
compared with only 1 for the standard protocol (Fig. 6A, right
panel). The sorts shared four CDR3s, and usage for TRBV27
and TRBVJ2-3 dominated (.60% of total reads) (Supplemental
Fig. 2).
Clonotypes not revealed by standard tetramer staining are
functionally relevant
The clonotyping of tetramer+ TILs revealed the TCR b-chain of
CD8 T cell clone CR24 (TRBV6-5/TRBJ2-7; CDR3b, CAS-
SYSFTEATYEQYF) in standard and optimally stained samples
(red triangles, Fig. 6A). As expected, CR24 stained well with a
standard tetramer protocol (Fig. 6B, upper left panel), hence its
appearance in the standard-stained TILs. The TCR from the
previously described (12) clone VB6G4.24 (TRBV24-1/
TRBJ2-1; CDR3b, CATSDRGQGANWDEQF) appeared only
in the optimally stained TILs (red rhombus, Fig. 6A) and re-
quired the optimized protocol for staining as a clone (Fig. 6B,
lower left panel). Both of these clones recognize the wild-type
peptide (EAAGIGILTV) and the commonly used heteroclitic
version (ELAGIGILTV) (40) of the melan A/MART1 peptide
(Fig. 6B, middle panels) and kill autologous tumor (Fig. 6B,
right panels). Thus, the VB6G4.24 clone that cannot be stained
by standard pMHC tetramer staining protocols and that is
not recovered from TILs using such a protocol is functionally
efficacious.
To further validate that the additional T cells revealed by
optimized pMHC tetramer staining belong to clones that are
functional, we performed further HLA A2–ELAGIGILTV
tetramer-based sorts of MM909.24 TILs to grow clones, for
tetramer staining and functional analysis, as outlined in Fig. 1.
In total, 62 clones were grown, 13 from the standard stained
TILs and 49 from the optimally stained TILs (Fig. 7A, 7B, left
panels). Clones from the standard-stained TILs were tetramer
negative (CR14; Fig. 7A, middle panel) or stained sufficiently
with the standard protocol (CR1; Fig. 7A, right panel). Im-
portantly, all of the clones from the optimized sort stained
with tetramer using the optimized protocol, but only some of
these clones stained with the standard protocol (Fig. 7B).
Clone CR27 fell into the latter category; this clone stained
only with an optimized protocol that included PKI and cross-
linking of pMHC multimer with anti-fluorochrome Ab
(Fig. 7B, right panel). Clonotypic analysis of clones that re-
quired the optimized protocol to stain, revealed that clone
CR31 expressed a TCR b-chain that was only recovered from
TILs with the optimized staining protocol (red circle, Fig. 6B;
TRBV30/TRBJ1-5; CDR3b, CAWSSQGLGQPQHF). Although
this clone failed to stain with standard pMHC tetramer staining
(Fig. 7C, left panel), it was efficient at recognizing peptide (Fig. 7C,
middle panel) and patient-autologous tumor cells (Fig. 7C, right
panel).
We next spiked HLA A2neg PBMCs with clone CR31 at ∼2%
of CD3+ cells and stained the resulting mix with a standard
pMHC tetramer protocol or optimized protocol that included
PKI and Ab cross-linking (Fig. 8A). The standard protocol
failed to recover this functionally efficient T cell, but we were
able to recover it with the optimized protocol. We next un-
dertook similar recovery experiments with three more melan
A/MART1 clones at a level ∼ 5% CD3+ cells. Clones MEL13
and CR29 stain well with standard pMHC tetramer staining
and could be recovered very cleanly with the standard pro-
tocol (Fig. 8B, middle and bottom panels). In contrast,
VB6G4.24 clone, which kills the autologous melanoma cell
efficiently (12), could not be recovered by standard pMHC
tetramer staining, but it could be recovered with the optimized
protocol (Fig. 8B, top panels). Thus, VB6G4.24, which like
CR31 is efficient at recognizing the autologous melanoma
cell, could not be detected by standard pMHC tetramer
staining protocols. Overall, these experiments demonstrate
that clones with TCRs revealed by optimized pMHC staining
can be functionally relevant and missed by standard staining
protocols.
Clonotypes that require an optimal protocol to stain with
tetramer are functionally dominant in patient blood following
successful immunotherapy
As described above, melanoma patient MM909.24 underwent a
complete lasting remission following TIL therapy (39). The TIL
infusion product (cryopreserved and without further in vitro
passage) used in the clinic to cure patient MM909.24, as well
as blood (PBMCs) taken after complete remission, were stim-
ulated with autologous melanoma, and responding cells
(TAPI-0 assay) were sorted for clonotypic analysis by TRBV
sequencing. Reactivity toward melanoma was 46% for TILs
and 3.4% for blood (Fig. 9). Three CDR3s found in TILs
and blood (CASSNGFHFNTLYF, CASTLGGGTEAFF, and
CATSDRGQGANWDEQFF) originated from T cells with
melan A specificity and had required an optimal tetramer pro-
tocol to stain in previous experiments (Fig. 6). The last CDR3 is
expressed by clone VB6G4.24, which was characterized in
Fig. 6 to be an avid killer of autologous melanoma, yet required
the optimal protocol to stain. Impressively, these functional
clonotypes dominated the response, amassing 44% (22.4, 14.3,
and 7.3%, respectively) of all tumor-reactive CDR3s in the
blood of patient MM909.24 after complete remission, which
represented a substantial enrichment compared with the infused
TILs (0.12, 0.04, and 0.34%, respectively) (Fig. 9). The CDR3
(CASSYSFTEATYEQYF) of melan A clone CR24 (Fig. 6) was
also seen, but at a much lower frequency (0.003% in TILs and
0.09% in blood). CR24 exhibits good cytotoxicity toward au-
tologous melanoma and stains with tetramer under standard
conditions (Fig. 6). Although not the primary aim of this study,
the experiments conducted in Figs. 6 and 9 allowed us to define
the specificities (HLA A2, melan A ELAGIGILTV) of the two
dominant persistent melanoma-reactive clonotypes found in the
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FIGURE 8. A standard tetramer protocol was not sufficient for detecting low-affinity melan A clones from PBMCs. (A) Recovery of CR31 spiked
(aiming for 2% of CD3+ cell) into HLA A2neg PBMCs by standard (tetramer-alone) and optimized (tetramer + PKI + anti-PE Ab) (red boxes) staining
protocols with HLA A2–ELAGIGILTV (heteroclitic residue in bold) and irrelevant tetramers (ALWGPDPAAA from preproinsulin15–24). (B) Recovery of
melan A–specific clones VB6G4.24 (top panels), MEL13 (middle panels), and CR29 (bottom panels) spiked into HLA A2neg PBMCs (aiming for 5% of
CD3+ cells) and stained using a standard or optimized staining protocol, as in (A), with HLA A2–ELAGIGILTV and irrelevant (ILAKFLHWL from
hTERT540–548) (67) tetramers. Clone VB6G4.24 stains only with the optimized protocol (red box, top right panel). Gating: lymphocytes and then viable
CD3+/CD14neg/CD19neg cells. Plots are displayed as smoothed, with outliers and large dots. Percentages are shown for the respective gates. Spiked clones
exhibit a high CD8 expression relative to those from PBMCs and can be visualized by CD8 staining alone.
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blood of patient MM909.24 after complete remission. In sum-
mary, melanoma-reactive T cells that could only be visualized
using optimal tetramer staining (Figs. 6–8) were shown to be
fully functional in in vitro (Figs. 6, 7) and ex vivo (Fig. 9)
settings. Additionally, TCR clonotypes associated with these
T cells were persistent and dominant in vivo and, therefore,
were highly likely to be involved in the lasting remission ex-
perienced by patient MM909.24.
Differences in staining efficacy between standard and
optimized pMHC tetramer staining protocols are independent
of temperature
We perform our tetramer staining on ice, whereas other researchers
sometimes use room temperature or 37˚C. Therefore, we com-
pared staining of TIL samples, in which there was a sizable
tetramer+ population, with HLA A2-EAAGIGILTV and HLA
A2-ELAGIGILTV at 4˚C, room temperature (∼22˚C), and 37˚C.
FIGURE 9. Melanoma-reactive T cells in the blood of a patient cured of cancer are dominated by clonotypes that require an optimal protocol to stain with melan A
tetramer. (A) The clinical TIL infusion product used to induce a complete lasting remission (.5 y and counting) of metastatic melanoma in HLA A2+ Patient
MM909.24, as well as PBMCs taken after cure, were stimulated with autologous melanoma for 5 h in the presence of TAPI-0 and Abs for CD107a and TNF.
Responding T cells (percentage shown in each gate) were sorted by flow cytometry for high-throughout sequencing of the TRBV. Gating: lymphocytes, single cells,
and CD3+ ViViDneg cells. (B) Unique TCR b-chain clonotypes displayed as vertical slices of the respective TIL or blood charts. CDR3b of persistent melan A–specific
T cells are shown in red. The blue boxes indicate TCRs that require an optimal protocol to stain, and the black box indicates a TCR that stains with a standard protocol
(Fig. 6). CDR3s of clones VB6G4.24 (red rhombus, needs optimal staining) and CR24 (red triangle, stains with standard protocol) appeared in the melanoma-reactive
populations in TILs and blood. The VB6G4.24 clonotype was the fifth most frequent of the clones that responded to tumor in patient blood after treatment.
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Higher temperatures were observed to increase the number of
CD8+Tet+ cells slightly (Supplemental Fig. 3A). Importantly, the
differences in staining efficacy between standard and optimized
protocols were independent of temperature (Supplemental Fig.
3A). Staining of PBMC samples at higher temperatures is known
to increase nonspecific background (18) (Supplemental Fig. 3B).
FIGURE 10. Optimized pMHC multimer staining revealed low-affinity Ag-specific cells. (A) PBMCs from HLA A2+ Donor 0439 were stained ex vivo by flow
cytometry in parallel using HLA A2 IMP2366–376 (NLSALGIFSTG) peptide tetramer alone (standard) or in combination with PKI and anti-fluorochrome Ab (op-
timized). The percentage of tetramer+ cells of CD8+ T cells is shown for each gate. Irrelevant tetramer made with HLA A2–ALWGPDPAAA preproinsulin-derived
peptide (residues 15–24) (66) was used to set the gates for sorting. CD8+Tet+ cells were sorted for TCR sequencing and CDR3 analysis of b-chains (right panel).
Clonotypes are displayed as sort-shared (gray) or sort-unique (blue) sections of a pie, with each section for each sort corresponding to a different CDR3. The number
of shared (gray) and unique (blue) CDR3s for the respective sorts are shown in the center of each pie. (B) CR0439.NLS CD8+ T cell clone grown from Donor 0439’s
PBMCs stained weakly for the cognate Ag with the standard protocol and showed improved binding to tetramer with the optimized protocol (left panel). HLA A2–
ALWGPDPAAA irrelevant tetramer was used as control. Mean fluorescence intensities are displayed according to the key. The clone responded well to cognate
peptide (middle panel), as assessed by MIP-1b release, and exhibited killing of IMP2-expressing melanoma cells (right panel) in a chromium-release assay after 4 and
18 h. (C) Recovery of CR0439.NLS clone spiked (aiming for 1% of CD3+ cell) into HLA A2neg PBMCs by standard (red box) or optimized (red box) staining
protocols with HLA A2–NLSALGIFSTG and irrelevant HLA A2–ILAKFLHWL (hTERT540–548) tetramers.
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The signal/noise ratio of preproinsulin15–24 dextramer-stained
PBMCs from patients with type 1 diabetes was greatly reduced
when performed at 37˚C; hence, we favored staining on ice.
Standard pMHC tetramer staining fails to detect functional
tumor-specific T cell clonotypes in direct ex vivo
PBMC samples
The above experiments with tumor-specific T cells were under-
taken with cultured TILs. We next examined T cells specific for a
different self-epitope in direct ex vivo PBMCs, a situation in which
pMHC tetramer staining is more commonly used. For these studies,
we selected IMP2, which is a member of a family of three con-
served oncofetal Ags that is known to be very highly expressed
between the zygote and embryo stages (52) IMP2 is also known to
be expressed by some cancers (53–55), and there are hypotheses
that the IMPs, especially IMP3, have an oncogenic role, although
this role appears to have stemmed from association with aggres-
sive and advanced cancers rather than any mechanistic insight (56,
57). More recent reports have suggested that IMP2 acts as a tumor
promoter by stabilizing oncogenic mRNAs encoding HMGA1
(58), preventing let-7 target gene silencing (59) and it can be
crucial for preserving cancer stem cells in an in vitro model sys-
tem (60). We have determined that residues 366–376 of IMP2
(NLSALGIFST) are presented on the surface of HLA A2+ cells
expressing IMP2 and represent a novel HLA A2–restricted epitope
(G. Dolton, C. Rius, S.A.E. Galloway, B. Szomolay, V. Bianchi,
A. Wall, M. Donia, P. thor Straten, I.M. Svane, and A.K. Sewell,
manuscript in preparation).
To determine whether our optimized pMHC staining method-
ology could identify tumor-specific T cells in direct ex vivo PBMCs
that were not detected by standard pMHC tetramer staining, we
performed ex vivo sorts with the HLA A2–restricted IMP2 se-
quence NLSALGIFST. Using the strategy outlined in Fig. 1, only
0.002% of cells stained with cognate pMHC tetramer in com-
parison with 0.05% staining with the optimized protocol
(Fig. 10A, left panel). Analysis of TCR b-chain repertoires used
by CD8+Tet+ sorted cells by high-throughput sequencing revealed
13 CDR3s for the standard tetramer–stained cells (69 cells sorted)
and 31 CDR3s for the optimized staining (324 cells sorted).
Twenty-one unique CDR3b sequences were detected with the
optimized protocol (Fig. 10, right panels). Ex vivo sorts were
repeated at a different time point and revealed 15 CDR3s se-
quences for the standard tetramer–stained cells compared with 91
CDR3s for the optimized tetramer staining from 156 and 731
sorted cells, respectively (Supplemental Fig. 4). As before, we
grew monoclonal T cell populations from the optimally sorted
population from donor 0439. Clone CR0439.NLS (TRAV40/TRAJ53;
CDR3a, CLTPSGGSNYKLTLF; TRBV11-3/TRBJ2-5; CDR3b,
CASAAYGETQYF) failed to stain with the standard pMHC tetramer
protocol. Our optimized protocol increased the mean fluorescence in-
tensity of staining of this clone by .30-fold (Fig. 10B). The CR0439.
NLS clone responded well to cognate NLSALGIFSTG peptide and
killed melanoma cells (MM909.24) expressing IMP2 (Fig. 10B), as
confirmed by intracellular staining with anti-IMP2 Ab (data not
shown). This fully functional NLSALGIFSTG-specific T cell clone
could not be recovered using standard pMHC tetramer staining when it
was spiked into PBMCs (Fig. 10C). In contrast, our optimized protocol
recovered this clone with ease (Fig. 10C).
Discussion
The application of pMHC multimer staining has transformed the
study of Ag-specific T cell populations (9), and these reagents have
been central to a great number of research studies. Several recent,
somewhat alarming, reports have indicated that pMHC staining
might fail to detect the majority of functional T cells (12, 18, 19)
and have prompted suggestions that T cell immunology has be-
come biased toward the type of cells amenable to detection with
multimeric pMHC (24). We stained healthy PBMCs with pMHC
tetramers specific for HLA A2–restricted epitopes from influenza,
CMV, EBV, and IMP2. Additionally, we examined staining for
yellow fever virus–specific cells in a vaccinated donor and tumor-
specific T cells in the TILs that were used to induce a complete
lasting remission in a patient with stage IV melanoma. Several
recent studies have suggested that pMHC multimer staining fails
to detect fully functional T cells and, thereby, underestimates the
size of Ag-specific T cell populations. This failure is thought to be
especially prominent when low-affinity TCRs predominate, such
as in MHCII-restricted responses or those directed against self-
antigens. Antiviral TCRs are known to bind to their cognate
pMHC Ags with relatively high affinity (13, 49), and it has been
assumed that standard pMHC tetramer staining is proficient at
revealing such cells. We made use of an optimized staining pro-
tocol that included use of the PKI dasatinib during staining to
prevent “unproductive” TCR downregulation without the capture
of pMHC multimer (36) and a fluorochrome-specific Ab to cross-
link pMHC multimer and reduce its dissociation from the cell
surface during cell washing (12). Parallel staining with optimized
and standard protocols recovered similar cell populations from the
PBMCs of healthy HLA A2+ donors stained with pMHC tetramers
of the influenza M1 epitope GILGFVFTL, CMV pp65 epitope
NLVPMVATV, and EBV LMP2A epitope CLGGLLTMV. Although
both protocols recovered similar T cell populations for these Ags, in
each case staining with the optimized protocol had the advantage of
being considerably brighter without an adverse signal/noise issue.
Although pMHC tetramer staining with the above viral epitopes
identified similar CD8+Tet+ T cell populations, this was not the
case with all viral epitopes. Optimized staining with the EBV
BMLF1280–288 epitope GLCTLVAML identified larger populations
of CD8+Tet+ T cells than could be detected with a standard protocol
in five of six donors tested. This situation was further pronounced
with yellow fever virus–specific T cells. We also demonstrated that
regular pMHC tetramer staining of TIL samples failed to identify
fully functional clonotypes that recognized low concentrations of
cognate peptide and were efficient at killing the autologous tumor.
The functionality of these clones was further confirmed by the
enrichment of clonotypes requiring optimized pMHC tetramer
in the blood of a “cured” patient. Indeed, just three persistent
clonotypes, all of which could not be stained with standard
pMHC tetramer staining, accounted for 44% of the entire re-
sponse to tumor in patient blood following cure, suggesting that
these clonotypes may have played a major role in cancer
clearance.
We extended this finding by demonstrating that tetramer staining
with IMP2-specific reagents failed to recover fully functional
clonotypes from fresh PBMCs unless our optimized protocol was
used. Our results are in accordance with other studies that have
found that functional T cells fail to stain with cognate pMHC
multimer (19, 24, 25, 61, 62). Our findings also agree with studies
showing that higher-order pMHC multimers, such as pMHC
dextramers (11) and dodecamers (18), can recover larger func-
tional T cell populations than recovered by pMHC tetramer
staining performed in parallel. The proportion of Ag-specific
T cells that is missed by regular pMHC tetramer staining varies
widely but can be extremely substantial. Fifty to ninety percent of
the T cells that could be recovered by staining TILs and PBMCs
with HLA A2–ELAGIGILTV dextramers in the presence of
PKI and Ab cross-linking could not be detected by standard
pMHC tetramer staining (12). Overall, we have found that pMHC
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tetramer staining can miss a substantial proportion of T cells that
can be detected with optimized staining in several systems. These
findings appear to be consistent with those of other research
groups. Lymphocyte choriomeningitis virus glycoprotein– and
oligodendrocyte glycoprotein–specific murine CD4 T cell pop-
ulations were underestimated by 4- and 8-fold by pMHCII tetra-
mers (19); pMHC dodecamers, which have 12 pMHC molecules
per reagent, were able to detect 2–5-fold more Ag-specific human
and murine CD4 and CD8 T cells compared with the equivalent
tetramers (18). Khan et al. (23) showed that very large populations
(5% of total CD8 T cells) in a CMV-seropositive donor respon-
ded to the HLA A2–restricted peptide VLEETSVML by intra-
cellular cytokine staining, but these cells could not be recovered
with HLA A2–VLEETSVML tetramer, and all 14 VLEETSVML-
reactive clones isolated in this study failed to stain with the cog-
nate tetrameric pMHC reagent. Other studies also show that T cell
function need not correlate with pMHC multimer staining (19–21)
and suggest that these reagents may have routinely underestimated
the size of Ag-specific T cell populations over the last 20 y. Im-
portantly, the optimized protocol described in this article was
observed to recover many more clonotypes than recovered by
standard protocols, including those proven to be functionally
relevant. It remains to be seen whether an optimized protocol that
includes high-valency pMHC multimers, dasatinib treatment, and
pMHC cross-linking with Ab can recover all of the T cells capable
of responding to a particular Ag. However, because dasatinib
treatment and pMHC cross-linking can be applied to any pMHC
multimer stain at a cost , $0.05 per sample, we recommend that
this “control” is always used to maximize T cell recovery (or to
confirm that it is already maximal). Our results with Donor 0439
and pMHC tetramers of the EBV BMLF1280–288 epitope HLA
A2–GLCTLVAML were particularly noteworthy, because re-
peated attempts to stain this EBV-seropositive donor with this
tetramer failed .15 y ago. Therefore, we assumed that this donor
did not respond to this epitope. Prescreening of HLA A2+ PBMCs
from laboratory-based healthy donors by ELISPOT indicated that
as many as 0.1% of the T cells in PBMCs from Donor 0439
responded to GLCTLVAML peptide. Re-examination with stan-
dard pMHC tetramer staining for this study confirmed that these
cells stained extremely poorly. Application of our optimized
technology, which was unavailable at the time of our initial
screening, showed that 0.15% of CD3+ cells stained with HLA
A2–GLCTLVAML tetramer. A clone grown from this population
recognized low concentrations of cognate peptide in the context of
HLA A2 and responded to Donor 0439’s autologous EBV-infected
LCL. This fully functional T cell clone could not be recovered
using standard pMHC tetramer staining when it was spiked into
PBMCs, but it was easily distinguishable when we applied our
optimized protocol.
It has been suggested that the extensive use of pMHC multimer
staining over the last 20 y may have introduced a bias that has
continually underestimated the lower-affinity, but functional,
components within diverse Ag-specific TCR repertoires (24).
Accumulating evidence suggests that T cells with very low–af-
finity TCRs can make important contributions to immunity in vivo
(24, 25, 61–63). Further work will be required to understand how
these weak interactions, which could challenge simplistic kinetic
proofreading models of TCR triggering (64), are able to precipi-
tate T cell activation.
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